Mankind Pharma Limited — Credit Ratings, 25-02-2025: Credit Rating

ICRA Limited has reaffirmed the credit ratings for Mankind Pharma Limited’s instruments. The company's non-convertible debentures of ₹5,000 crore (Cr) maintain a rating of [ICRA]AA+ with a stable outlook. Additionally, long-term and short-term fund-based limits of ₹1,250 crore (Cr) have received reaffirmation, with long-term rated at [ICRA]AA+ (Stable) and short-term at [ICRA]A1+. The commercial paper remains intact with a rating of [ICRA]A1+.

This reaffirmation signals a strong credit profile, likely reflecting stable revenue generation and effective debt management. The stable outlook indicates expectations of continued financial health, positioning the company well amidst sector challenges. Rating stability can enhance borrowing conditions, potentially lowering costs for future financing, which can facilitate growth initiatives. Investors should consider this stability as a positive indicator for maintaining confidence in the firm’s strategic direction and operational integrity.